NCT05413850 - Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

August 27, 2026

Study Completion Date

March 31, 2028

Conditions

Prostate CancerMetastatic Castration-resistant Prostate CancermCRPCUrogenital NeoplasmsProstatic NeoplasmsProstatic Diseases

Interventions

DRUG

Lutetium (177Lu) rhPSMA-10.1 Injection

Therapeutic cycles of 177Lu-rhPSMA-10.1

DIAGNOSTIC_TEST

18F-rhPSMA-7.3 injection (in phase 1 only)

18F-rhPSMA-7.3 (in phase 1 only) at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.

Trial Locations (5)

10065

COMPLETED

Weill Cornell Medicine - New York - Presbyterian Hospital, New York

33165

RECRUITING

Biogenix Molecular LLC, Miami

63110

RECRUITING

Washington University School of Medicine, St Louis

68130

RECRUITING

XCancer Omaha / Urology Cancer Center, Omaha

6525GA

RECRUITING

Radboud UMC, Nijmegen